MAP2K7 and chronic myelogenous leukemia, BCR-ABL1 positive: In this condition of BCR-ABL independent imatinib resistance, treatment with imatinib sustains RAF/MEK/ERK signaling, giving additional proliferative advance to CML-LSCs (24).